EdwardStadtmauerMD

Hematology • Philadelphia, PA

Hematologic Oncology

Professor, Medicine, Perelman School of Medicine

Join to view full profile

Dr. Stadtmauer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stadtmauer's full profile

Already have an account?

Office
3400 Civic Center Blvd
# 2
Philadelphia, PA 19104
Phone+1 215-615-5858

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1986 - 1989
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1983 - 1986
Perelman School of Medicine at the University of PennsylvaniaClass of 1983

Certifications & Licensure

PA State Medical License 1985 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Philadelphia Magazine Castle Connolly, 2005-2008, 2011-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
Completed
Phase 3
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2008 Dec 01
Unknown status
Phase 1
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
CT Antigen TCR-Engineered T Cells for Myeloma Start of enrollment: 2013 Oct 15
Terminated
Phase 1, Phase 2
CART-19 for Multiple Myeloma Start of enrollment: 2014 May 01
Completed
Phase 1
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Start of enrollment: 2018 Sep 05
Terminated
Phase 1
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Start of enrollment: 2018 Oct 15
Completed
Phase 1
Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma Start of enrollment: 2022 Mar 04
Completed
Not Applicable
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

113 citations
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Robert F. Cornell, Bonnie Ky, Brendan M. Weiss, Cherie N. Dahm, Deepak K. Gupta
Journal of Clinical Oncology. 2019-06-12
1 citations
Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Te...
Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario
Journal of Clinical Oncology. 2024-08-10
79 citations
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra
Leukemia. 2021-01-01

Journal Articles

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium Difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Edward A Stadtmauer, James K Mangan, Elizabeth O Hexner, David L Porter, Daria V Babushok, Jacqueline Smith, Craig W Freyer, Mindy Schuster, Noelle V Frey, Selina M Lu..., Clinical Infectious Diseases

Abstracts/Posters

Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)
Edward A. Stadtmauer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
Edward A. Stadtmauer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
Edward A. Stadtmauer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Lo...
Edward A. Stadtmauer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
2013 Updates in Oncology
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania - 6/25/2013
Join now to see all

Press Mentions

The Cancer Tech Revolution: ‘We’re Not Far from a Diagnosis Being No Big Deal’May 17th, 2023
Penn Medicine at the 2022 ASH MeetingDecember 8th, 2022
Where Should Society Draw Ethical Lines for Experimental CRISPR Gene Therapies That Appear Able to Cure Diseases?April 13th, 2022
Join now to see all